Bloomios, Inc. (BLMS) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BLMS representa a Bloomios, Inc., una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). Calificado con 49/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 17 mar 2026Bloomios, Inc. (BLMS) Resumen de Asistencia Médica y Tuberías
Bloomios, Inc. focuses on manufacturing and distributing a range of cannabidiol (CBD) products, including edibles, tinctures, and topicals. Operating within the specialty and generic drug manufacturing sector, the company targets both wholesale and retail distribution channels for its hemp-derived supplements and cosmetic products.
Tesis de Inversión
Bloomios, Inc. operates in the high-growth CBD market, but its financial performance and OTC listing present significant risks. With a negative profit margin of -226.7% and a market capitalization of $0.00B as of March 2026, the company's financial stability is uncertain. The company's gross margin stands at 36.7%. Key growth catalysts include expanding distribution channels and introducing new product lines. However, investors should be aware of the risks associated with OTC-listed companies, including limited liquidity and regulatory uncertainty. The company's ability to achieve profitability and navigate the competitive landscape will be critical to its long-term success.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market Cap of $0.00B indicates a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -0.00 reflects the company's current lack of profitability.
- Profit Margin of -226.7% highlights significant operational challenges and the need for improved cost management.
- Gross Margin of 36.7% suggests potential for profitability if operating expenses are better controlled.
- Beta of -0.53 indicates the stock is less volatile than the market, but this may also reflect limited trading activity.
Competidores y Pares
Fortalezas
- Diverse product range across multiple CBD categories.
- Established wholesale and retail distribution channels.
- Focus on hemp-derived supplements and cosmetic products.
- Experienced management team in the CBD industry.
Debilidades
- Negative profit margin and limited financial resources.
- Small market capitalization and OTC listing.
- Limited brand recognition compared to larger competitors.
- Dependence on the evolving regulatory landscape for CBD products.
Catalizadores
- Upcoming: Potential regulatory changes in the CBD market could create new opportunities or challenges for Bloomios.
- Ongoing: Expansion of distribution channels through strategic partnerships with retailers.
- Ongoing: Introduction of new and innovative CBD products to meet evolving consumer demand.
- Ongoing: Increased consumer awareness and acceptance of CBD products.
- Ongoing: Development of white label and private label opportunities to diversify revenue streams.
Riesgos
- Potential: Increased competition from larger companies entering the CBD market.
- Potential: Negative publicity or health concerns related to CBD products.
- Potential: Fluctuations in the price of hemp and other raw materials.
- Ongoing: Regulatory uncertainty and potential restrictions on CBD products.
- Ongoing: Limited financial resources and negative profit margin.
Oportunidades de crecimiento
- Expansion of Product Line: Bloomios can drive growth by introducing new and innovative CBD products, such as specialized formulations targeting specific health conditions or novel delivery methods. The market for CBD-infused beverages and edibles is projected to reach $2.8 billion by 2028, presenting a significant opportunity for Bloomios to capture market share through product innovation and effective marketing.
- Strategic Partnerships: Forming strategic partnerships with established retailers and distributors can significantly expand Bloomios' market reach and brand visibility. Collaborating with national pharmacy chains or health food stores could provide access to a broader customer base and enhance the company's credibility. The timeline for establishing such partnerships is estimated at 12-18 months, with potential revenue impact within the following year.
- E-commerce Expansion: Investing in a robust e-commerce platform and digital marketing strategies can enable Bloomios to reach a global audience and drive online sales. The online CBD market is experiencing rapid growth, with projections estimating a market size of $16 billion by 2027. By optimizing its online presence and offering a seamless customer experience, Bloomios can capitalize on this trend and increase its direct-to-consumer sales.
- White Label and Private Label Opportunities: Bloomios can leverage its manufacturing capabilities to offer white label and private label CBD products to other companies. This can provide a stable revenue stream and diversify the company's customer base. The market for white label CBD products is growing as more businesses seek to enter the CBD market without investing in their own manufacturing infrastructure. Bloomios can target small to medium-sized businesses in the health and wellness sector.
- International Expansion: Exploring international markets, particularly in Europe and Asia, can unlock significant growth opportunities for Bloomios. The European CBD market is projected to reach $1.5 billion by 2025, while the Asian market is also showing increasing interest in CBD products. However, international expansion requires careful consideration of regulatory requirements and cultural differences. Bloomios can start by targeting countries with more favorable CBD regulations and establishing partnerships with local distributors.
Oportunidades
- Expansion into new geographic markets.
- Development of innovative CBD formulations and delivery methods.
- Strategic partnerships with established retailers and distributors.
- Increased consumer awareness and acceptance of CBD products.
Amenazas
- Intense competition from other CBD manufacturers and distributors.
- Changing regulatory requirements and potential restrictions on CBD products.
- Fluctuations in the price of hemp and other raw materials.
- Negative publicity or health concerns related to CBD products.
Ventajas competitivas
- Product diversification across multiple CBD product categories.
- Established wholesale and retail distribution channels.
- Proprietary formulations and manufacturing processes.
- Brand recognition and customer loyalty in the CBD market.
Acerca de BLMS
Bloomios, Inc., formerly known as XLR Medical Corp., rebranded in April 2021 to concentrate on the cannabidiol (CBD) market. Incorporated in 2001 and headquartered in Santa Barbara, California, the company manufactures, markets, and distributes a diverse portfolio of CBD products. These include edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats. Bloomios distributes its hemp-derived supplements and cosmetic products through both wholesale partnerships and direct retail channels, aiming to capitalize on the growing consumer interest in CBD-based health and wellness solutions. The company's strategy involves expanding its product line and distribution network to reach a broader customer base in the competitive CBD market. Bloomios faces the challenges of navigating regulatory complexities and differentiating itself in a crowded field of CBD product manufacturers and distributors. The company's success depends on effective marketing, product innovation, and adherence to quality standards to build consumer trust and brand loyalty.
Qué hacen
- Manufactures cannabidiol (CBD) products.
- Markets CBD products through various channels.
- Distributes CBD products to wholesale and retail customers.
- Offers edibles, tinctures, oils, salves, capsules, balms, lotions, creams, and beverages.
- Provides CBD products for both human and pet consumption.
- Sells hemp-derived supplements and cosmetic products.
Modelo de Negocio
- Manufacturing and selling CBD products.
- Generating revenue through wholesale distribution to retailers.
- Generating revenue through direct-to-consumer retail sales.
- Offering a diverse range of CBD product categories to cater to different consumer preferences.
Contexto de la Industria
Bloomios, Inc. operates within the rapidly expanding CBD market, which has seen significant growth due to increasing consumer acceptance of CBD products for various health and wellness applications. The market is characterized by intense competition, with numerous companies offering similar products. Key trends include the development of innovative CBD formulations, the expansion of distribution channels, and increasing regulatory scrutiny. Bloomios competes with other CBD manufacturers and distributors, including AIDA, ASFX, CENBF, MJNE, and SAGD, all of which are navigating the evolving regulatory landscape and striving to establish brand recognition.
Clientes Clave
- Retail consumers seeking CBD products for health and wellness.
- Wholesale distributors and retailers selling CBD products.
- Pet owners seeking CBD products for their pets.
- Customers interested in various forms of CBD consumption (e.g., edibles, topicals, tinctures).
Finanzas
Gráfico e información
Precio de la acción de Bloomios, Inc. (BLMS): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para BLMS.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para BLMS.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para BLMS.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de BLMS en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Michael Hill
CEO
Michael Hill serves as the CEO of Bloomios, Inc., managing a small team of three employees. Information regarding his detailed career history, education, and previous roles is not available. His leadership is focused on guiding Bloomios in the competitive CBD market, navigating regulatory challenges, and driving growth through product innovation and distribution expansion.
Historial: Due to limited information on Michael Hill's prior experience and specific achievements at Bloomios, it is difficult to assess his track record. His success will be measured by the company's ability to achieve profitability, expand its market share, and navigate the evolving regulatory landscape for CBD products.
Información del mercado OTC de BLMS
The OTC Other tier represents the lowest tier of the OTC market, indicating that Bloomios, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be required to provide regular financial disclosures, increasing the risk for investors compared to companies listed on major exchanges like the NYSE or NASDAQ.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited liquidity due to low trading volume on the OTC market.
- Lack of transparency due to potentially limited financial disclosures.
- Higher price volatility compared to stocks listed on major exchanges.
- Potential for pump-and-dump schemes or other fraudulent activities.
- Regulatory uncertainty surrounding CBD products and the company's operations.
- Verify the company's financial statements and SEC filings (if available).
- Research the background and experience of the company's management team.
- Assess the company's competitive position in the CBD market.
- Evaluate the company's compliance with relevant regulations.
- Monitor news and press releases for any red flags or potential risks.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- The company has been in operation since 2001.
- Bloomios has a diverse product range across multiple CBD categories.
- The company has established wholesale and retail distribution channels.
- Bloomios rebranded in 2021 to focus on the CBD market, indicating a strategic shift.
- The company's headquarters are located in Santa Barbara, California.
BLMS Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar BLMS?
Bloomios, Inc. (BLMS) actualmente tiene una puntuación IA de 49/100, indicando puntuación baja. Fortaleza clave: Diverse product range across multiple CBD categories.. Riesgo principal a monitorear: Potential: Increased competition from larger companies entering the CBD market.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de BLMS?
BLMS actualmente puntúa 49/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de BLMS?
Los precios de BLMS se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre BLMS?
La cobertura de analistas para BLMS incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en BLMS?
Las categorías de riesgo para BLMS incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Increased competition from larger companies entering the CBD market.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de BLMS?
La relación P/E para BLMS compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está BLMS sobrevalorada o infravalorada?
Determinar si Bloomios, Inc. (BLMS) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de BLMS?
Bloomios, Inc. (BLMS) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Limited information available on CEO background and track record.
- Financial data based on available information and may not be comprehensive.
- OTC market investments carry higher risk than exchange-listed stocks.